COVID-19 VACCINATIONS: If, in addition to indemnity for your main employment, you would like cover for delivering COVID-19 Vaccinations please apply for our standalone extension Apply Today

Home  »   Latest News   »   PDA Position Statement on e-cigarettes

PDA Position Statement on e-cigarettes

The PDA believes that e-cigarettes should not be sold from a pharmacy until a suitable licensed product is available and urges the GPhC to review its premises standards policy to reduce the potential conflict between commercial decisions and professional autonomy.

Thu 6th March 2014 The PDA

The PDA believes that e-cigarettes should not be sold from a pharmacy until a suitable licensed product is available.  In keeping with the PDA’s philosophy of respecting its members’ professional judgement, we ask that they take into consideration the following information when arriving at a decision whether to sell e-cigarettes or not.

 

  • E-cigarettes are currently unlicensed products with no standardisation of safety, quality or efficacy

  • The availability of suitable licensed nicotine replacement products already offered through pharmacies

  • The risk that selling unlicensed e-cigarettes through pharmacies will legitimise such products and may confuse the public concerning their overall effectiveness and safety

  • The current media profile and advertising of e-cigarettes which may encourage non-smokers to experiment with these products and could normalise smoking behaviour and nicotine exposure

  • The undermining of any local NHS smoking cessation services provided though the pharmacy if e-cigarettes were sold

  • Some e-cigarette brands are owned by tobacco companies and sales of these brands contributes to the profits of a business whose primary product has major health risks.  Over 100,000 smokers in the UK die each year from smoking related causes

 

  • The GPhC position on e-cigarettes requires consideration of the guidance from appropriate bodies such as the MHRA and the RPS.  The RPS guidance is that “e-cigarettes should not currently be sold or advertised from pharmacies”

 

 

The commercial decision by some pharmacies to start selling e-cigarettes from registered premises appears to be in conflict with the guidance of the regulator and the RPS. This presents pharmacists with a dilemma where their instinct is to follow this guidance yet their employer is encouraging them to ignore it.

 

This example demonstrates how the friction between commercialism and professionalism can be problematic and leave pharmacists, the profession and ultimately patients exposed to the commercially driven agenda of employers.

 

In light of this, the PDA believes that the GPhC should urgently review its premises standards policy as recent developments demonstrate how these standards have been used to undermine the professionalism of pharmacy by the commercial agenda. It also exposes the potential difficulties for the profession and patients, concerning the GPhC’s current plans to allow superintendent pharmacists and owners to be the judge of whether P medicines can be sold on self-selection.

 

Pharmacists who feel under pressure from company managers to sell e-cigarettes against their professional judgement should contact the PDA for advice.

The Pharmacists' Defence Association is a company limited by guarantee. Registered in England; Company No 4746656.

The Pharmacists' Defence Association is an appointed representative in respect of insurance mediation activities only of
The Pharmacy Insurance Agency Limited which is registered in England and Wales under company number 2591975
and is authorised and regulated by the Financial Conduct Authority (Register No 307063)

The PDA Union is recognised by the Certification Officer as an independent trade union.

Cookie Use

This website uses cookies to help us provide the best user experience. If you continue browsing you are giving your consent to our use of cookies.

General Guidance Resources Surveys PDA Campaigns Regulations Locums Indemnity Arrangements Pre-Regs & Students FAQs Coronavirus (COVID-19)